Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Mar;3(1):29-40.
doi: 10.2147/tcrm.2007.3.1.29.

Therapy of autoimmune bullous diseases

Diya F Mutasim  1
Affiliations

Therapy of autoimmune bullous diseases

Diya F Mutasim. Ther Clin Risk Manag. 2007 Mar.

Abstract

Autoimmune bullous diseases result from an immune response to molecular components of the desmosome or basement membrane. Bullous diseases are associated with a high degree of morbidity and occasional mortality. Therapy of bullous diseases consists of suppressing the immune system, controlling inflammation and improving healing of erosions. The therapeutic agents used in the treatment of bullous diseases may be associated with high morbidity and occasional mortality. Successful treatment requires understanding of the pathophysiology of the disease process and the pharmacology of the drugs being used.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Algorithmic approach to the treatment of pemphigus vulgaris. Abbreviations: IVIg, intravenous immunoglobulin; MMF, mycophenolate mofetil.
Figure 2
Figure 2
Algorithmic approach to the treatment of bullous pemphigoid. Abbreviations: IVIg, intravenous immunoglobulin.
See this image and copyright information in PMC

References

    1. Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional treatment. J Am Acad Dermatol. 2001;45:679–90. - PubMed
    1. Ahmed AR, Colon JE. Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid. Arch Dermatol. 2001;137:1181–9. - PubMed
    1. Ahmed AR, Moy R. Azathioprine. Int J Dermatol. 1981;20:461–9. - PubMed
    1. Alijotas J, Pedragosa R, Bosch J, et al. Prolonged remission after cyclosporine therapy in pemphigus vulgaris: Report of two young siblings. J Am Acad Dermatol. 1990;23:701–3. - PubMed
    1. Amagai M, Hashimoto T, Shimizu N, et al. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg 3) produced by baculovirus. J Clin Invest. 1994;94:59–67. - PMC - PubMed

LinkOut - more resources